IFW

Attorney Docket No. 54275.8005.US03

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450. Alexandria, VA 22313-1450, on: Ketolier 21 2005 Dee Dee Sutherland PATENT OCT 2 4 2005 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE IN RE APPLICATION OF: ANNA P. CATANIA ET AL. EXAMINER: THURMAN K. PAGE ART UNIT: 1615 **APPLICATION NO.:** 10/659,053 FILED: **SEPTEMBER 8, 2003** CONF. NO: 3809 FOR: COMPOSITION AND METHOD OF TREATMENT FOR UROGENITAL CONDITIONS Supplemental information Disclosure Statement After First Office Action but Before Final Action or Notice of Allowance - 37 C.F.R. § 1.97(c) Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: 1. Timing of Submission This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 C.F.R. § 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application. 2. Cited Information Copies of the following references are enclosed: Ø All cited references References marked by asterisks The following: References with Cite Nos. B9 through B11.  $\boxtimes$ 

	Copies of the following references can be found in parent U.S. Applicat No. :							
		All cited references References marked by asterisks The following:						
	paten	This application was filed after 30 June 2003 and no copies of U.S. patents nor published applications are enclosed (See Notice of Deputy Commissioner Kunin on 11 July 2003).						
0	The following references are not in English. For each such reference, the undersigned has enclosed (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching Authority citing the reference, (iii) a copy of a reference which appears to be an English-language counterpart, or (iv) an English-language abstract for the reference prepared by a third party. Applicant has not verified that the translation, English-language counterpart or third-party abstract is an accurate representation of the teachings of the non-English reference, though, and reserves the right to demonstrate otherwise.							
		All cited references References marked by ampersands The following:						
Effect	of Info	rmation Disclosure Statement (37 C.F.R. § 1.97(h))						
that: exami results cited i applic art to	(i) a s nation s and t informa ant doo the sub	tion Disclosure Statement is not to be construed as a representation search has been made; (ii) additional information material to the of this application does not exist; (iii) the information, protocols, he like reported by third parties are accurate or enabling; or (iv) the ation is, or is considered to be, material to patentability. In addition, es not admit that any enclosed item of information constitutes prior bject invention and specifically reserves the right to demonstrate that erence is not prior art.						
Fee P	aymen	<u>t</u>						
		believed due because this Information Disclosure Statement is being he mailing date of the first Office Action.						
		eant further submits that no fee is due in light of the following cation under 37 C.F.R. § 1.97(e) (check only one):						
		In accordance with 37 C.F.R. § 1.97(e)(1), the undersigned hereby states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; or						

[54275-8005/LA051600.054] 2

3.

4.

In accordance with 37 C.F.R. § 1.97(e)(2), the undersigned hereby states that no item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c), more than three months prior to the filing of this statement.

However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2586.

## 5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted, Perkins Coie LLP

Date: Oct 20, 2005

Jóséph P. Hamilton Registration No. 51,770

Correspondence Address:

Customer No. 34055
Perkins Coie LLP
Patent – LA
P.O. Box 1208
Seattle, WA 98111-1208

Phone: (310) 788-9900 Fax: (310) 788-3399

## **COMPLETE IF KNOWN** 10/659,053 Application Number **INFORMATION DISCLOSURE** Confirmation Number 3809 PTATEMENT BY APPLICANT September 8, 2003 Filing Date Form PTO-1449 (Modified) First Named Inventor Anna P. Catania (Use see all sheets if necessary) Group Art Unit 1615 Thurman K. Page Examiner Name Attorney Docket No. 54275.8005.US03

Stage	<u>t                                      </u>	&/_	of		<u>l</u>	1 .	Attorney Docket No.	54275.8005.US0	3	
137	2	.6%								
_	PADEM	AF			U.S. F	PATENT	DOCUMENTS			
Examiner Initials*	Cite	U.S.		Code		Name of Patentee or Inventor of Cited Document		Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	B8	6,800	0.291		Lipton et al. 10/05/04					
		<del> </del>	_•							
				F	OREIG	N PATE	NT DOCUMENTS			
Examiner	Cite				nd Code	· · · · · · · · · · · · · ·		Date of Publication or Filing Date of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant	
Initials*	No.	Office	NUMBER	(if	known)	of	Cited Document	Document	Figures Appear	+
	B9	wo	87/04623					08/13/87		$\square$
	B10	EP	0335662					10/04/89		
	<u> </u>		OTHER P	RIOR	ART-NO	ON PATE	NT LITERATURE D	OCUMENTS		
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.  T  LIPTON, J.M., "The Neuropeptide Alpha-Melanocyte-Stimulating Hormore Inhibits Experimental Arthritis in Rats," Neuroimmunomodulation 1:28-32 (1994).								Т
	B11									
										Ш
					<u> </u>			<u>.</u>	<del></del>	
									<u> </u>	+
									·	

EXAMINER		DATE CONSIDERED			
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not				
	considered. Include copy of this form with next communication to application(s).				

Ų,